Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice.

Diabetologia

Cardiovascular Biochemistry Laboratory, CRCHUM (7-134), Tour Viger, 900 St-Denis St., Montreal, Quebec, H2X 0A9, Canada.

Published: June 2014

Aims/hypothesis: Obesity and diabetes increase the risk of developing cardiovascular diseases and heart failure. These metabolic disorders are generally reflected by natriuretic peptide system deficiency. Since brain natriuretic peptide (BNP) is known to influence metabolism and cardioprotection, we investigated the effect of chronic exogenous BNP treatment on adverse myocardial consequences related to obesity and diabetes.

Methods: Ten-week-old C57BL/KsJ-db/db obese diabetic mice (db/db) and their lean control littermates (db/+) were treated with BNP (0.6 μg kg(-1) h(-1)) or saline for 12 weeks (n = 10/group). Serial blood and tomography analysis were performed. Cardiac function was determined by echocardiography, and biochemical and histological heart and fat analyses were also performed.

Results: BNP treatment resulted in an average increase in plasma BNP levels of 70 pg/ml. An improvement in the metabolic profile of db/db mice was observed, including a reduction in fat content, increased insulin sensitivity, improved glucose tolerance and lower blood glucose, despite increased food intake. db/db mice receiving saline displayed both early systolic and diastolic dysfunction, whereas these functional changes were prevented by BNP treatment. The cardioprotective effects of BNP were attributed to the inhibition of cardiomyocyte apoptosis, myocardial fibrosis, cardiac hypertrophy and the AGE-receptor for AGE (RAGE) system as well as normalisation of cardiac AMP-activated protein kinase and endothelial nitric oxide synthase activities.

Conclusions/interpretation: Our results indicate that chronic BNP treatment at low dose improves the metabolic profile and prevents the development of myocardial dysfunction in db/db mice.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00125-014-3201-4DOI Listing

Publication Analysis

Top Keywords

db/db mice
16
bnp treatment
16
natriuretic peptide
12
brain natriuretic
8
prevents development
8
obese diabetic
8
bnp
8
metabolic profile
8
treatment
5
db/db
5

Similar Publications

Purpose: The retina contains the highest concentration of the omega 3 fatty acid, docosahexaenoic acid (DHA), in the body. Although epidemiologic studies showed an inverse correlation between the consumption of omega 3 fatty acids and the prevalence of diabetic retinopathy, there are no data showing the effect of diabetes on retinal DHA in humans. In this study, we measured the DHA content of the retina in diabetic and non-diabetic humans as well as mice and determined the effect of diabetes on retinal thickness and function in mice.

View Article and Find Full Text PDF

Mass Spectrometry Imaging Reveals Spatial Metabolic Alterations and Salidroside's Effects in Diabetic Encephalopathy.

Metabolites

December 2024

Key Laboratory of Mass Spectrometry Imaging and Metabolomics, Minzu University of China, National Ethnic Affairs Commission, Beijing 100081, China.

Diabetic encephalopathy (DE) is a neurological complication of diabetes marked by cognitive decline and complex metabolic disturbances. Salidroside (SAL), a natural compound with antioxidant and neuroprotective properties, has shown promise in alleviating diabetic complications. Exploring the spatial metabolic reprogramming in DE and elucidating SAL's metabolic effects are critical for deepening our understanding of its pathogenesis and developing effective therapeutic strategies.

View Article and Find Full Text PDF

Background: Diabetes often causes diabetic nephropathy (DN), a serious long-term complication. It is characterized by chronic proteinuria, hypertension, and kidney function decline, can progress to end-stage renal disease, lowering patients' quality of life and lifespan. Inflammation and apoptosis are key to DN development.

View Article and Find Full Text PDF
Article Synopsis
  • Diabetic kidney disease (DKD) is a major cause of kidney failure, largely due to damage in podocytes, which are essential for kidney function.
  • Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key player in protecting cells from oxidative stress, making it a promising target for DKD therapies.
  • The study found that DDO-1039, a new Nrf2 activator, improved kidney health in diabetic mice by reducing podocyte injury, lowering blood sugar levels, and decreasing inflammation, endorsing its potential as a treatment for DKD.
View Article and Find Full Text PDF

Low expression of Frataxin might contribute to diabetic peripheral neuropathy in a mouse model.

Biochem Biophys Res Commun

December 2024

Yancheng Clinical College, Xuzhou Medical University, Yancheng, 224000, PR China. Electronic address:

Diabetes is one of the most prevalent metabolic disorders, and its incidence has been experiencing a steady annual rise in recent years. Diabetic peripheral neuropathy (DPN) represents the most frequent adverse complication, exerting a profound impact on the quality of life for those suffering from diabetes. The etiology of DPN is complex, including impaired mitochondrial function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!